

## 510(k) Summary

**Prepared:** July 15, 2010

AUG 17 2010

**Submitter/Holder:**

**Company Name:** Canon Inc.  
**Company Address:** 30-2 Shimomaruko 3-chome, Ohta-ku  
Tokyo 146-8501, Japan  
**Contact Person:** Naoyasu Asaka  
**Phone Number:** 81-3-3758-2111  
**Fax Number:** 81-3-5482-3960

**Proposed Device:**

**Reason For 510(k):** New Model  
**Trade Name:** Canon Inc.  
**Model Name:** CXDI-70C Wireless  
**Classification Name:** 90MQB, Solid State X-ray Imager  
**FDA 510(k) #:** To be assigned

**Predicate Device:**

**Trade Name:** Canon Inc.  
**Model Name:** CXDI-55C  
**Classification Name:** 90MQB, Solid State X-ray Imager  
**FDA 510(k) #:** K091545

**Trade Name:** Canon Inc.  
**Model Name:** CXDI-31  
**Classification Name:** 90MQB, Solid State X-ray Imager  
**FDA 510(k) #:** K003689

**Description of Device:**

The DIGITAL RADIOGRAPHY CXDI-70C Wireless is a solid state x-ray imager which has approx. 35x43cm imaging area.

The DIGITAL RADIOGRAPHY CXDI-70C Wireless intercepts x-ray photons and the scintillator of the CXDI-70C Wireless emits visible spectrum photons that illuminate an array of photo-detectors that create an electrical signals.

After the electrical signals are generated, it is converted to digital value, and the images will be displayed on monitors. The digital value can be communicated to the operator console via wiring connection or wireless.

**Intended Use:**

DIGITAL RADIOGRAPHY CXDI-70C Wireless provides digital image capture for conventional film/screen radiographic examinations.

The device is intended to replace radiographic film/screen systems in all general purpose diagnostic procedures.

This device is not intended for mammography applications.

*Section 10: Summary*

**Comparison to Predicate:**

The CXDI-70C Wireless's imaging principle and intended use are the same as those of CXDI-55C. Pixel pitch used in CXDI-70C Wireless is different from CXDI-55C, however, most of the specifications are the same or better than CXDI-55C.

**Conclusion:**

The Performance Data demonstrate that CXDI-70C Wireless is as safe and effective as the predicate devices (DIGITAL RADIOGRAPHY CXDI-55C and CXDI-31). Based on the information in this submission, similarity to the predicate devices, and the results of our design control activities and non-clinical testing, it is the opinion of Canon Inc. that the DIGITAL RADIOGRAPHY CXDI-70C Wireless described in this submission is substantially equivalent to the predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room – WO66-G609  
Silver Spring, MD 20993-0002

Canon, Inc. – Medical Equipment Group  
% Mr. Koji Kubo, Manager  
Cosmos Corporation, Tokyo Office  
3F 2-17-6 Akebono-cho  
Tachikawa-shi, Tokyo 190-0012  
JAPAN

Re: K102012  
Trade/Device Name: CXDI-70C Wireless  
Regulation Number: 21 CFR 892.1680  
Regulation Name: Stationary x-ray system  
Regulatory Class: II  
Product Code: MQB  
Dated: July 15, 2010  
Received: July 16, 2010

AUG 23 2013

Dear Mr. Kubo:

This letter corrects our substantially equivalent letter of August 17, 2010.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,



Janine M. Morris  
Acting Director  
Division of Radiological Devices  
Office of In Vitro Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

K102012

### Indications for Use

510(k) Number (if known): **k102012**

Device Name: Cannon CXDI-70C Wireless

**Indications for Use:**

Digital Radiography CXDI-70C Wireless provides digital image capture for conventional film/screen radiographic examinations.

The device is intended to replace radiographic film/screen systems in all general purpose diagnostic procedures.

This device is not intended for mammography applications.


Prescription Use  (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_ (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)



(Division Sign-Off)

Division of Radiological Devices

Office of *In Vitro* Diagnostic Device Evaluation and Safety

510(k) Number K102012